Skip to main content

Table 1 Baseline Characteristics

From: Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

VariablesUnweightedIPTW Weighted
Historical
Controls
N = 140
2nd line Ipilimumab
N = 189
P-valueHistorical
Controls
N = 288.4
2nd line Ipilimumab
N = 311.2
Weighted standardized difference
Age at second line (years), mean (SD)55.2 (12.7)61.7 (13.6)<.00157.5 (18.5)59.5 (17.9)0.11
Males, n (%)96 (68.6)127 (67.2)0.7966.63%67.71%0.02
Income quintile, n (%)  0.41   
 Lowest18 (12.9)20 (10.6) 11.47%10.39%0.03
 Medium to Low21 (15.0)28 (14.8) 15.73%16.47%0.02
 Medium37 (26.4)37 (19.6) 26.00%16.99%0.22
 Medium to High28 (20.0)52 (27.5) 19.88%26.89%0.17
 Highest36 (25.7)52 (27.5) 26.93%29.26%0.05
Urban, n (%)121 (86.4)167 (88.4)0.6088.53%89.12%0.02
Austin morbidity score, mean (SD)15.9 (11.3)16.5 (11.9)0.6315.99 (16.8)16.1 (15.4)0.01
Number of ADGs, median (IQR)8 (6–10)9 (6–11)0.218.3 (4.5)8.5 (4.4)0.04
Charlsons score, n (%)  0.15   
 0123 (87.9)149 (78.8) 83.5%82.5%0.03
 1+17 (12.1)40 (21.2) 16.5%17.5%0.08
Prior radiation (any), n (%)79 (56.4)105 (55.6)0.8855.40%56.00%0.01
Prior radiation of brain, n (%)30 (21.4)46 (24.3)0.5422.37%22.98%0.01
Prior radiation other than brain, n (%)65 (46.4)74 (39.2)0.1945.04%40.20%0.1
Prior resection (any), n (%)102 (72.9)139 (73.5)0.8955.40%56.00%0.01
Prior brain resection, n (%)<=513 (6.9)0.194.99%6.63%0.07
Prior other resection, n (%)12 (8.6)9 (4.8)0.166.69%6.68%0
Time from diagnosis to start of second line (months), median (IQR)32.5 (11.9–57.5)18.0 (8.4–38.5)0.00739.942.90.04
Time from end of first-line treatment to start of second-line treatment (months), median (IQR)1.7 (1.0–3.3)1.0 (0.7–1.7)< 0.0011.82.60.19
Time from diagnosis to start of first line (months), median (IQR)23.7 (6.5–54.1)12.6 (4.1–33.7)< 0.00135.136.90.03
First-line treatment, n (%)  < 0.001   
 Chemotherapy110 (78.6)119 (63.0) 81.7%58.4%0.53
 BRAF/MEK13 (9.3)59 (32.3) 9.7%36.9%0.68
 Non-ipilimumab Immunotherapy8 (5.7)8 (4.2) 5.2%4.0%0.06
 Others9 (6.4)<= 5 3.5%0.7%0.19
  1. *Percentage shown in the table is column %
  2. Abbreviation: SD Standard Deviation, IQR Interquartile range, ADG Adjusted Diagnosis Groups;